

## Supplement







Figure S1. PRISMA flowchart for the studies included and reasons for studies excluded from the systematic review. HF: heart failure, RCT: randomized control trial.



**Figure S2. Cochrane tool for assessment of quality of the included studies**



**Figure S3. Funnel plot demonstrating no signs of publication bias for volume depletion**



**Figure S4. Funnel plot demonstrating no signs of publication bias for AKI**

Table S1. Fragility of results from trials with SGLT2 inhibitor and meta-analysis of these trials

Outcome	Meta-analysis			
	Events/ Total SGLT2i	Events/ Total Placebo	FI/ RFI	FQ
Hypotension	219/4836	202/4846	21*	0.002
Volume depletion	473/5019	438/5031	19*	0.001
AKI	95/4888	140/4899	14	0.001

\* - Reverse fragility index/Reverse fragility quotient

**Abbreviations:** SGLT2i = sodium-glucose cotransporter 2 inhibitor; FI=fragility index; RFI= reverse fragility index; FQ= fragility quotient; AKI= acute kidney injury;